Clinical Trial Update: A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-masked trial comparing evening dosing of Xalacom in glaucoma and ocular hypertension; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle
• Ocular Hypertension

Drugs mentioned

• Xalacom (latanoprost/timolol)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Status: COMPLETED